MktsMarkets

Relay Therapeutics, Inc.
NASDAQ: RLAYKey statistics
RLAY News
Stories mentioning RLAY from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 3,000 | 6,999 | 0.00 | 677.00 | 7,679 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | ||||||||
| Sales General & Admin | ||||||||
| Total Operating Expenses | 81,590 | 67,630 | 80,391 | 77,524 | 92,548 | 84,979 | 96,369 | 100,757 |
| Operating Income (Loss) | (78,590) | (60,631) | (80,391) | (76,847) | (84,869) | (84,979) | (96,369) | (100,757) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 5,299 | 5,741 | 6,242 | 6,472 | 7,804 | 8,975 | 8,264 | 8,545 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (73,291) | (54,890) | (74,149) | (70,375) | (77,065) | (76,004) | (88,105) | (92,212) |
| Earnings Per Share (Basic) | (0.41) | (0.32) | (0.43) | (0.41) | (0.46) | (0.53) | (0.63) | (0.69) |
| Earnings Per Share (Diluted) | (0.41) | (0.31) | (0.43) | (0.41) | (0.46) | (0.42) | (0.63) | (0.69) |
| Weighted Average Shares Outstanding (Basic) | 179,849 | 171,587 | 172,389 | 171,265 | 169,233 | 142,868 | 140,229 | 132,822 |
| Weighted Average Shares Outstanding (Diluted) | ||||||||
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About RLAY
Relay Therapeutics, Inc. (NASDAQ: RLAY) is a stock listed on the Nasdaq Stock Market under the ticker symbol RLAY. It last traded at $16.51 (Nov 18, 2026, 4:00 PM ET), up 0.2% on the day. That gives Relay Therapeutics a market capitalisation of $3.6B.
Over the past 52 weeks RLAY has traded between $6.17 and $21.27.
Revenue for the quarter ended Mar 31, 2026 was $3.0M; a net loss of $73.3M. Revenue was down 60.9% from $7.7M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $3.0M | -$73.3M | -2443.0% |
| Dec 31, 2025 | $7.0M | -$54.9M | -784.3% |
| Sep 30, 2025 | $0 | -$74.1M | — |
| Jun 30, 2025 | $677.0K | -$70.4M | -10395.1% |
From Relay Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…